PCI has unveiled its new brand identity at CPhI, reflecting the full integration of recently acquired businesses Penn Pharma and Biotec Services International, which significantly expand PCI’s drug development services.

Penn Pharma, headquartered in Wales, UK. added clinical and commercial dosage form manufacturing and packaging, labeling, and global storage, distribution and return drug services. The Biotec Services acquisition also expanded PCI’s presence in the UK/EU to support global investigational studies with additional packaging, storage and distribution capacity, as well as consulting services for clinical trial supplies.

Headquartered in Philadelphia, PA, PCI now has operations in North America and Europe. All parts of the PCI organization will now operate under the PCI Pharma Services name and brand. The combined PCI business provides full service ‘molecule to market’ pharma services to global customers, taking compounds from the earliest stages of development through to launch and ongoing supply. Services include: drug development, analytical services, clinical trial supply including drug manufacture, packaging and labeling, as well as global storage and distribution services, and commercial services including manufacturing, packaging, and serialization.

Bill Mitchell, PCI president and chief executive officer, said, “We strive to position PCI to best support our clients in bringing new medicines to successful commercialization. Our continued investments expand the broad service offerings we can provide clients as they enter clinical study, progress towards commercial launch, and ultimately aid in their market competitiveness throughout the product’s lifecycle. The new brand is reflective of the expanded scope of services and the partnership we enjoy with our clients.”

MR. Mitchell added, “Since its creation in 2013, PCI has focused on strategic investments and acquisitions with a strategy to best support our client needs with a model of industry-leading expertise, world-class facilities, and cutting edge technologies. This unique blend enables us to address evolving global drug development needs at each stage of the product lifecycle.”k